Dr. Richard F. Jacobs

Biographical Sketch

Richaard JacobsRobert H. Fiser, Jr. M.D. Professor of Pediatrics
Chairman, Department of Pediatrics
University of Arkansas for Medical Sciences
President, Arkansas Children’s Hospital Research Institute
Pediatrician-in-Chief, Arkansas Children’s Hospital

Richard F. Jacobs, M.D. is currently the Robert H. Fiser, Jr., Endowed Chair in Pediatrics and the Chairman of the Department of Pediatrics/University of Arkansas for Medical Sciences (UAMS). Dr. Jacobs is also currently the President of the Arkansas Children’s Hospital Research Institute (ACHRI). He received his M. D. degree from UAMS in 1977 and completed his Infectious Diseases fellowship training in 1982 at the University of Washington in Seattle, Washington.

Since joining the faculty at UAMS and Arkansas Children’s Hospital (ACH) in 1982, his biomedical research program has been continuously funded by the National Institute on Allergy and Infectious Diseases through the Collaborative Anti-viral Study Group (CASG). He has served on the NIH Advisory Board and as chairman of three protocol-specific advisory committees for the NIH/NIAID/CASG during this 28 year association. He also participates as an investigator on the Pediatric Pharmacology Research Unit (PPRU), funded by NIH/NICHD, in the ACHRI program. The primary goal of the PPRU is to study the pharmacokinetics (PK) and pharmacodynamics (PD) of different classes of medications in babies, infants and children.

He is the recipient of the Founder’s Award from the Southern Society for Pediatric Research for his research and mentoring of young clinician-scientists. He received the Distinguished Service Award from the Pediatric Infectious Diseases Society for his work as President and on the society’s Fellowship Training Program. He was the section chief of Pediatric Infectious Diseases at UAMS/ACH for 16 years. He is the author of over 200 peer-reviewed publications.

His research interests include the clinical and translational research trials of neonatal-infant anti-viral treatment of congenital and perinatal viral infections (CASG). The PPRU trials focus on the PK and PD evaluation of anti-infectives in babies, infants and children to provide dosing, dosing interval, safety and toxicity for compounds currently approved and available in adults.